Dr Cynthia Levy presented encouraging results from Ipsen's Phase 2* ELMWOOD trial (NCT05627362) assessing elafibranor (ELA) at two doses (80mg and 120mg) in PSC.

ELA was well tolerated by the patients in the trial. Blood markers started to improve in the 80mg and 120mg dose groups after 4 weeks. At week 12, both liver blood test results and itch improved for the higher dose group (120mg).

These findings support larger and longer term investigations of elafibranor to explore its therapeutic potential as a treatment for people with PSC.

Ask the Expert

Dr Palak Trivedi will join us in a special Ask the Expert in a couple of weeks (date to be confirmed) giving us a fantastic chance to ask questions and find out more about NCA.

*More information about clinical trial phases.